ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AGY Allergy Therapeutics Plc

3.00
0.00 (0.00%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Allergy Therapeutics Plc LSE:AGY London Ordinary Share GB00B02LCQ05 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.00 2.80 3.20 3.00 3.00 3.00 120,404 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 59.59M -43.07M -0.0090 -3.33 142.99M

Allergy Therapeutics PLC Allergy to host KOL webinar on VLP Peanut

07/09/2021 7:00am

RNS Non-Regulatory


TIDMAGY

Allergy Therapeutics PLC

07 September 2021

Allergy Therapeutics plc

("Allergy Therapeutics", "ATL" or the "Group")

Allergy Therapeutics to host KOL webinar on VLP Peanut vaccine candidate

7 September 2021 Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology pharmaceutical company specialising in allergy vaccines, today announces that it will host a webinar entitled 'VLP Peanut; a next generation peanut allergy immunotherapy', on Friday 17 September 2021 at 14.00 BST, 09.00 EDT.

The webinar will include an introduction from Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, and a feature presentation by key opinion leader (KOL), Dr. Mo Shamji, Reader in Immunology & Allergy at Imperial College London.

Dr. Shamji will summarise the findings of the Group's ex vivo VLP Peanut 001 biomarker study which, as announced on 3 August 2021, showed the hypoallergenic potential of the vaccine candidate, due to enter the clinic in Q1 2022.

Dr. Matt Heath, Principal Scientist at Allergy Therapeutics, will also provide an overview presentation on the Group's novel virus-like particle (VLP) technology.

The presentation will be followed by a live Q&A session and details can be accessed on the Group's website at https://www.allergytherapeutics.com/investors/results-reports-and-presentations/ . A replay of both will be made available on the website shortly after the event.

- ENDS -

For further information, please contact:

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Chief Financial Officer

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / David Daley / Carina Jurs

allergytherapeutics@consilium-comms.com

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved over 9% compound annual growth since formation, employs c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com .

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUNVKRASUKRAR

(END) Dow Jones Newswires

September 07, 2021 02:00 ET (06:00 GMT)

1 Year Allergy Therapeutics Chart

1 Year Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

1 Month Allergy Therapeutics Chart

Your Recent History

Delayed Upgrade Clock